Kiniksa Pharmaceuticals Ltd (KNSA)vsEli Lilly and Company (LLY)
KNSA
Kiniksa Pharmaceuticals Ltd
$76.27
-0.27%
HEALTHCARE · Cap: $6.13B
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 9374% more annual revenue ($79.67B vs $840.85M). LLY leads profitability with a 33.5% profit margin vs 9.6%. LLY trades at a lower P/E of 37.7x. LLY earns a higher WallStSmart Score of 76/100 (B+).
KNSA
Buy53
out of 100
Grade: C-
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$202.69
Current Price
$76.27
$126.42 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.4% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 30.4% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
Trading at 9.1x book value
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity, EPS Growth. Revenue growth of 55.4% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : KNSA
The primary concerns for KNSA are Price/Book, P/E Ratio. A P/E of 79.3x leaves little room for execution misses.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
KNSA is growing revenue faster at 55.4% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 53/100), backed by strong 33.5% margins and 47.7% revenue growth. KNSA offers better value entry with a 77.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical needs, particularly in the realm of autoimmune disorders. Its flagship candidate, KPL-404, is a monoclonal antibody designed to effectively modulate immune responses, positioning Kiniksa at the forefront of promising therapeutic advancements. The company boasts a strong clinical pipeline supported by strategic partnerships that enhance its research and development capabilities. With a dedication to transforming treatment paradigms and a robust growth trajectory, Kiniksa represents an attractive opportunity for institutional investors seeking impactful investments in the evolving healthcare landscape.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?